CERE News and Press, Ceres Inc. From 08/01/22

The following slide deck was published by Cerevel Therapeutics Holdings, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Cerevel Therapeutics Holdings, Inc. 2022 Q2 - Results - Earnings Call Presentation

Cerevel Therapeutics Holdings, Inc. (CERE) Q2 2022 Earnings Conference Call August 01, 2022, 08:00 AM ET Company Participants Matt Calistri - Vice President of Corporate Strategy and Investor Relations Tony Coles - Chairperson and Chief Executive Officer Ray Sanc...

Cerevel Therapeutics press release ( NASDAQ: CERE ): Q2 GAAP EPS of -$0.61 misses by $0.13 . Cash, cash equivalents and marketable securities as of June 30, 2022, were $531.2 million, inclusive of $37.5M from the tavapadon risk-sharing arrangement received in April 202...

Initiated two parallel, adequately-powered Phase 2 trials of emraclidine in schizophrenia with data expected 1H 2024 Phase 1 trial of emraclidine to be initiated by year-end to support future development in Alzheimer’s disease psychosis Panic disorder selected as ...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings for companies due to report...

CAMBRIDGE, Mass., July 25, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report second quarter 2022 financial results on Monday, August 1, ...

Cerevel is a CNS specialist drug developer formed as a result of a spinout of former Pfizer neuroscience assets. The company listed via a merger with a SPAC, which gave it ~$350m in funding, together with $150m raised privately. There are 3 lead assets - Emraclidine in schizophren...

Biopharmaceutical companies Athira Pharma ( ATHA ) and BioXcel Therapeutics ( BTAI ) have outperformed the gains in the biotech space on Thursday after Mizuho launched their coverage on small and mid-cap names focused on the central nervous system (CNS). Despite being a high...

Treatments for schizophrenia – a truly complex disease--are plagued with a high late-stage trial failure rate. Phase 3 KarXT results will be released this quarter. It will be a binary event. Despite cash balance issues and new clinical stage competitors, market  indica...

CAMBRIDGE, Mass., June 15, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has appointed Suneet Varma to serve as a member of its board of di...